Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Incyte

Do Wall Street Analysts Like Incyte Corporation Stock?

Wall Street is keeping a confident yet pragmatic stance on Incyte Corporation, supported by steady growth and a promising pipeline.

Barchart

Earnings Preview: What To Expect From Incyte's Report

Incyte is scheduled to release its fourth-quarter results soon, with analysts projecting double-digit surge in its bottom line figure.

Barchart

Is Incyte Stock Outperforming the Nasdaq?

Despite Incyte’s outperformance relative to the Nasdaq Composite over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Incyte's New Therapy Shows Signs Of 'Disease-Modifying' Potential In Rare Blood Cancer

Incyte Corporation (NASDAQ:INCY) on Sunday revealed new clinical data from two Phase 1 studies of INCA033989 for mutCALR-expressing myeloproliferative neoplasms (MPNs) at the 2025 American Society of Hematology (ASH) Annual Meeting.

Benzinga

Incyte Delivers Robust Growth, But 2028 Patent Expiry Still Looms

Incyte Corporation's (NASDAQ:INCY) third-quarter revenue was $1.37 billion. The company beat the consensus of $1.26 billion.

Benzinga

1 Growth Stock Under $100 to Buy Before It Soars

This biotech under $100 looks like a growth opportunity worth grabbing before it soars.

Barchart

Incyte's Quarterly Earnings Preview: What You Need to Know

Incyte will release its third-quarter earnings later this month, and analysts anticipate a double-digit bottom-line growth.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Is Incyte Stock Outperforming the S&P 500?

As Incyte has outperformed the S&P 500 recently, analysts remain moderately optimistic about the stock’s prospects.

Barchart

FDA Expands Incyte's Opzelura Approval To Treat Atopic Dermatitis In Children

The U.S. Food and Drug Administration (FDA) on Thursday approved Incyte Corporation’s (NASDAQ:INCY) announced Opzelura (ruxolitinib) cream 1.5% for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised children two years of age and older whose disease is not well controlled with topical prescription…

Benzinga

Can Incyte Deliver on 447% EPS Forecasts and Pipeline Hype?

Analysts expect nearly 450% EPS growth in 2025, making execution on its core portfolio critical for sustaining the outperformance experienced so far YTD.

MarketBeat

Are Wall Street Analysts Predicting Incyte Stock Will Climb or Sink?

Incyte has outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.

Barchart

This Incyte Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Friday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Benzinga

Incyte Surges Past Expectations With Strong Q2, Boosts Guidance On Jakafi Demand

Incyte Corporation (NASDAQ:INCY) reported on Tuesday that its second-quarter revenue was $1.22 billion, up 16% year over year. The company beat the consensus of $1.15 billion.

Benzinga

Incyte’s Q2 2025 Earnings: What to Expect

Incyte is gearing up to report its fiscal second-quarter earnings later this month, with analysts forecasting a sharp surge in profitability, projecting triple-digit year-over-year profit growth.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

How Is Incyte’s Stock Performance Compared to Other Biotech Stocks?

Incyte has underperformed relative to its biotech peers over the past year, though Wall Street analysts maintain a cautiously optimistic view on the stock’s outlook.

Barchart

Is Wall Street Bullish or Bearish on Incyte Stock?

Despite Incyte’s underperformance relative to the S&P 500 over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

Barchart

Incyte Earnings Preview: What to Expect

Incyte is all set to release its fiscal first-quarter earnings later this month, and analysts project a high double-digit profit growth.

Barchart

Are Wall Street Analysts Bullish on Incyte Stock?

Incyte has continued to observe strong demand for Jakafi and Opzelura, leading to robust growth in sales, and analysts remain bullish on the stock’s prospects.

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

What You Need to Know Ahead of Incyte's Earnings Release

Biopharma major Incyte is expected to announce its fourth-quarter results later this month and analysts expect a significant double-digit growth in earnings.

Barchart

Is Incyte Stock Outperforming the Dow?

Incyte has outperformed the Dow recently, and analysts remain moderately optimistic about the stock’s prospects.

Barchart

Is Incyte Stock Underperforming the Nasdaq?

Despite Incyte’s underperformance relative to the Nasdaq Composite over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Barchart

Incyte Stock: Is Wall Street Bullish or Bearish?

While Incyte has underperformed the broader market over the past year, Wall Street analysts remain moderately bullish about the stock’s prospects.

StockNews.com

3 Value Stocks With Strong Fundamentals to Buy Now

Value investing is highly favored as it focuses on purchasing undervalued stocks with solid fundamentals, providing the potential for high returns with lower risk and a disciplined, long-term approach. Therefore, it could be wise to invest in fundamentally sound, value stocks Expedia Group (EXPE), Incyte (INCY), and Albertsons Companies (ACI)…

StockNews.com

3 Biotech Gems Poised for April Breakthroughs

The biotechnology industry is expected to grow rapidly due to rising demand for personalized medicines, increased R&D spending, and the adoption of AI in the biopharma market. Hence, quality biotech stocks Incyte (INCY), Jazz Pharmaceuticals (JAZZ), and Exelixis (EXEL) could be poised for breakthroughs this month. Read more….

Barchart

2 Best Growth Stocks to Buy with $1,000 Right Now

Growth stocks are getting ready for a comeback year in 2024, and these two under-the-radar stocks have solid financials and significant upside potential.

1 2 3

People

William Blair

49 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Albertsons Companies Inc

Jazz Pharmaceuticals plc

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.